Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Developmental Disorder Therapeutics.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RARB drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RARB Recombinant / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View RARB Products |
| Gene Delivery | RARB Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View RARB Products |
| Benchmark Ab | Anti-RARB (Sequence of Benchmark) Recombinant positive control. |
View RARB Products |
| Validator | RARB siRNA Set For knockdown verification. |
View RARB Products |
| Related Target A | RARA Isoform selectivity counter-screening. |
View RARA Products |
| Related Target B | RXRA Heterodimerization partner for functional assays. |
View RXRA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| RAR Isoform Cross-Reactivity (Off-target effects) | Homolog panel proteins (RARA, RARB, RARG) strictly verified by mass spec and sequence analysis. |
| Intracellular Target Accessibility | High-purity soluble proteins available for biochemical binding assays (SPR/FP) and PROTAC screening. |
| Lack of Controls | Benchmark antibodies included for assay standardization. |
| False Positives in Cell Assays | Validated siRNA included for specificity checks and genetic knockdown. |
Live RARB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RARB therapeutics is intensifying, with major players shifting focus from traditional pan-retinoids to highly selective small molecules and targeted protein degraders (PROTACs). As a critical nuclear receptor and tumor suppressor, RARB represents a highly valuable target in oncology (e.g., breast cancer, neuroblastoma). The next wave of R&D is focusing on isoform-specific modulation to maximize efficacy while mitigating the classic toxicities associated with retinoid therapy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Agonist) | Roche, Pfizer (historical/pan) | Solid Tumors, Dermatology | Selectivity Assay (Need RARA/B/G panel proteins) |
| PROTAC / Degrader | Emerging Biotechs | Refractory Cancers | Ternary Complex Validation (Need High-purity Recombinant RARB) |
| Gene Therapy | Academic/Early Stage | Neurological Disorders | Expression Validation (Need specific Benchmark Abs) |